Abbott's new Proclaim™ Plus spinal cord stimulation system offers the next generation of stimulation therapy, giving physicians the ability to treat multi-site and evolving pain The system ...

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more ...

Abbott Laboratories ABT said Tuesday that its spinal cord stimulation (SCS) devices were approved by the U.S. Food and Drug Administration to treat people with chronic back pain who aren’t ...

ABBOTT PARK, IL / ACCESSWIRE / December 29, 2022 / Abbott (NYSE:ABT) today announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna™ spinal cord stimulation (SCS ...

A noninvasive therapy delivering gentle spinal stimulation was shown to slow disease progression and extend survival in an ...

Pain comes in many forms, and Abbott aims to treat as many as it can with its devices. The company received a new approval from the FDA for its low-dose spinal cord stimulator implant, covering ...

Abbott Laboratories received U.S. FDA approval for an expanded indication for its spinal cord stimulator (SCS) devices to include treatment of chronic back pain for individuals who have not had or are ...

People with spinal muscle atrophy (SMA), an inherited neuromuscular disease, usually experience muscle weakness that impacts movement. New research suggests that electrical spinal cord stimulation ...

ABBOTT PARK, Ill., Aug. 23, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved its new Proclaim™ Plus spinal cord stimulation ...

The new indication for Abbott' s Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more ...

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more ...

The FDA has approved Abbott Laboratories (NYSE: ABT) new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy. The next generation of Abbott's proprietary BurstDR ...